(RTTNews) - Alvotech (ALVO) has entered into supply and commercialization agreements with Sandoz (SDZ.SW) covering multiple biosimilar candidates in Canada, and in Australia and New Zealand. Sandoz ...

REYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients ...

As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade, the generic and biosim specialist sees a multibillion-dollar opportunity ...

(RTTNews) - Sandoz Group AG (SDZ.SW) announced that the European Commission has approved Ondibta (insulin glargine), a biosimilar to Sanofi's Lantus SoloStar, for the treatment of diabetes mellitus ...

As drug pricing pressure intensifies and benefit structures shift, some health systems are still treating biosimilars as a selective cost lever — deploying them in certain payer segments while ...

Please provide your email address to receive an email when new articles are posted on . Nufymco is indicated for the treatment of patients with a number of retinal diseases. The VEGF inhibitor is the ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Every day, I think about the patients waiting for medicines that could change, or even save, their lives. For them, access is not a statistic. It is hope, health, and a chance for a better future.

Data demonstrate a high degree of similarity between Armlupeg and the reference product. The Food and Drug Administration (FDA) has approved Armlupeg ™ (pegfilgrastim-unne), a biosimilar to Neulasta ® ...

Armlupeg, a biosimilar to Neulasta, is approved for reducing febrile neutropenia in non-myeloid malignancy patients undergoing myelosuppressive chemotherapy. Lupin's FDA-approved facility in India ...